Premium
Sry‐like high‐mobility group box antibody‐related paraneoplastic cerebellar degeneration in the background of underlying non‐small cell lung cancer
Author(s) -
Onder Halil,
Kurtulan Olcay
Publication year - 2016
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12311
Subject(s) - medicine , paraneoplastic cerebellar degeneration , lung cancer , cerebellar degeneration , pathology , cancer , lambert eaton myasthenic syndrome , neurological examination , antibody , myasthenia gravis , surgery , autoantibody , immunology , cerebellum
Background Paraneoplastic neurological syndromes ( PNS ) are defined as all non‐metastatic neurological complications of cancer in which no other etiologies, such as vascular, infectious or metabolic, were determined. Recently, Sry‐like high‐mobility group box ( SOX 1) antibody associated with PNS has been described, and is associated with Lambert–Eaton myasthenic syndrome, paraneoplastic cerebellar degeneration and paraneoplastic peripheral neuropathy invariably in the background of underlying small‐cell lung cancer. Case presentation A 75‐year‐old man was admitted to our neurology clinic at Hacettepe University Hospital, Sihhiye, Ankara, Turkey with complaints of imbalance and memory impairment that had started 2 months earlier and progressively increased. Neurological examination showed a state of delirium in the background of rapid progressive dementia and severely truncal ataxia. Cranial magnetic resonance imaging was unremarkable; however, in further investigations, thoracic tomography yielded bilateral hilar lymphadenopathy, and paraneoplastic antibody investigations resulted in positive SOX 1 antibody. The following thoracic excisional lymph node biopsy investigations supported the diagnosis of non‐small‐cell lung cancer and paraneoplastic cerebellar degeneration associated with SOX 1 antibody in the background of non‐small‐cell lung cancer. Adjuvant chemotherapy was started, but the patient deteriorated, which prevented proper plasmapheresis therapy. He died in the second month of admission as a result of severe sepsis leading to septic shock. Conclusions Here, we show the second case diagnosed with PNS in association with non‐small‐cell lung cancer. We note the importance of SOX 1 antibody as a marker for PNS , and suggest that investigations of this antibody be carried out in larger case studies.